# BioAtla, Inc. (BCAB) — merger/definitive [pending]
Source: SEC API (secapi.ai) · situation sit_481ac2ceb84f2da35f6d · retrieved 2026-08-11T15:49:41.264Z

## Overview
BioAtla, Inc. is a biopharmaceutical company developing therapeutic antibodies and related biologics; the company is listed on Nasdaq and is subject to minimum bid price listing requirements.

BioAtla, Inc. entered into a merger agreement on January 30, 2026, with its wholly owned subsidiary BA Merger Sub, Inc., whereby Merger Sub will merge with and into BioAtla, with BioAtla as the surviving corporation. The merger will effect a 1-for-50 reverse stock split, converting every 50 shares of outstanding common stock into one share. The merger also amends BioAtla's certificate of incorporation to remove supermajority voting requirements for future amendments to the capital stock provisions. The transaction requires approval by a majority of outstanding common shares, with stockholders voting at a special meeting scheduled for March 4, 2026. The reverse split is intended to help BioAtla regain compliance with Nasdaq's $1.00 minimum bid price requirement and maintain its listing on The Nasdaq Capital Market.

## Terms
- Counterparty: BA Merger Sub, Inc.

## Key dates
- Announced 2026-02-11 · Record 2026-02-02 · Vote 2026-03-04

## Timeline
- 2026-02-11 · DEFM14A (0001539497-26-000331): DEFM14A - BioAtla, Inc. — *BioAtla, Inc. is a biopharmaceutical company developing therapeutic antibodies and related biologics; the company is listed on Nasdaq and is subject to minimum bid price listing requirements.* BioAtla, Inc. entered into a merger agreement on January 30, 2026, with its wholly owned subsidiary BA Merger Sub, Inc., whereby Merger Sub will merge with and into BioAtla, with BioAtla as the surviving corporation. The merger will effect a 1-for-50 reverse stock split, converting every 50 shares of outstanding common stock into one share. The merger also amends BioAtla's certificate of incorporation to remove supermajority voting requirements for future amendments to the capital stock provisions. The transaction requires approval by a majority of outstanding common shares, with stockholders voting at a special meeting scheduled for March 4, 2026. The reverse split is intended to help BioAtla regain compliance with Nasdaq's $1.00 minimum bid price requirement and maintain its listing on The Nasdaq Capital Market.
  https://www.sec.gov/Archives/edgar/data/1826892/0001539497-26-000331.txt

## Citations
- 0001539497-26-000331 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000153949726000331